Evaluation of the efficacy and safety of adalimumab therapy in pediatric patients with Crohn’s disease

Journal Title: Postępy Nauk Medycznych - Year 2015, Vol 28, Issue 11

Abstract

Introduction. Crohn’s disease belongs to the group of inflammatory bowel disease(IBD). Prompt diagnosis and early optimal treatment warrants successful outcome,which is disease remission. Introduction of biological drugs for the treatment of IBD increasedthe efficiency of remission.Aim. The aim of the study was to evaluate the effectiveness of induction and maintenanceremission of the disease and safety of adalimumab therapy in pediatric patients withCrohn’s disease.Material and methods. The study included 9 patients with Crohn’s disease with meanage 7.35 years at diagnosis. All patients were treated in the past with IFX or ADA. To assessthe severity of the disease and the effectiveness of treatment authors used PCDAIscale (Pediatric Crohn’s Disease Activity Index) and value of laboratory tests – ESR, CRP,hemoglobine, hematocrite – during enrolment to therapy, after third dose and after 6 and12 months of treatment. The authors assessed safety of adalimumab therapy by evaluationof adverse events occurring during the drug administration and between doses.Results. 8 patients (89%) achieved induction of remission, 1 patient (11%) didn’t respond tothe treatment, while this is the patient previously treated both IFX and ADA. Regard to adverseevents (AE), the authors did not register any AE during administration of the drug, and thosewhich occurred between doses of the drug were not different from those in a healthy population.Conclusions. Adalimumab therapy allows to induction and maintenance remission.The safety profile of adalimumab in pediatric population is comparable with that seen inthe adult population.

Authors and Affiliations

Dorota Jarzębicka, Joanna Sieczkowska, Grzegorz Oracz, Jarosław Kierkuś

Keywords

Related Articles

Undernutrition, malnutrition and wastage of food

On the one hand, there were 925 million people undernourished worldwide in 2010, and on the other hand, 1.3 billion tons of food (about one third of global food production) are lost or wasted annually. The biggest number...

Jak uniknąć błędów w codziennej praktyce w postępowaniu z chorym na niedokrwistość?

W kontaktach lekarzy niespecjalistów z chorym na niedokrwistość można pokusić się o wyróżnienie wśród nich błędów ogólnych dotyczących podejścia do niedokrwistości bez względu na charakter niedokrwistości oraz błędów bar...

Assessment of nutritional status and quality of life of patients with alcoholic liver cirrhosis

Introduction: Excessive ethanol consumption results in alcoholic liver disease, and eventually in liver cirrhosis. The aim of the study was to assess nutritional status and quality of life of patients with alcoholic live...

Niemy klinicznie guz chromochłonny u kobiety z androgenizacją

Kobieta, lat 29, została przyjęta do Kliniki Endokrynologii CMKP z powodu objawów androgenizacji i hiperandrogenemii, z podejrzeniem nieklasycznej formy wrodzonego przerostu nadnerczy. Ustalono rozpoznanie zespołu PCO. S...

Stroke in the elderly – abnormalities

Consistent ageing of the society leads to higher stroke incidence. Within next 20 years stroke incidence is expected to increase by 40%. Most of strokes will occur in the elderly population. Apart from age, the most impo...

Download PDF file
  • EP ID EP77370
  • DOI 10.5604/08606196.1190918
  • Views 172
  • Downloads 0

How To Cite

Dorota Jarzębicka, Joanna Sieczkowska, Grzegorz Oracz, Jarosław Kierkuś (2015). Evaluation of the efficacy and safety of adalimumab therapy in pediatric patients with Crohn’s disease. Postępy Nauk Medycznych, 28(11), 800-805. https://www.europub.co.uk/articles/-A-77370